Class I PI3K signaling is one of the most frequently hyperactivated pathways in breast cancer, and its crosstalk with other signaling pathways contributes to the limited efficacy of PI3K-targeted therapeutics. This evidence concerns the gene PIK3CD and breast carcinoma.